Kymera Therapeutics (KYMR) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Vaxcyte (PCVX) over the past year, gaining 74.6% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +114.4% for KYMR. Kymera Therapeutics is the larger company by market cap ($9.84 billion vs $8.77 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | PCVX |
|---|---|---|
| Share price | $115.31 | $55.39 |
| Market cap | $9.84B | $8.77B |
| 1-day change | -3.42% | -5.09% |
| YTD return | +48.19% | +20.05% |
| 1-year return | +74.61% | +15.93% |
| 5-year return | +114.37% | +178.90% |
| EPS (TTM) | $-3.64 | $-8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.21M | — |
| Revenue growth (YoY) | -16.70% | — |
| Net income (latest FY) | $-311.35M | $-766.63M |
| Gross margin | 0.00% | — |
| Operating margin | -891.07% | — |
| Net margin | -794.04% | — |
| 52-week high | $142.92 | $90.75 |
| 52-week low | $63.69 | $42.40 |
| Distance from 52-week high | -19.32% | -38.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +25.94% | +110.15% |
| Average volume | 852.46K | 2.19M |
| Shares outstanding | 85.37M | 158.30M |
| Employees | 285 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed PCVX by 58.7 percentage points over the past year.
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
KYMR vs PCVX FAQ
Which is bigger, Kymera Therapeutics or Vaxcyte?
Kymera Therapeutics (KYMR) is larger, with a market capitalization of $9.84B compared with $8.77B for Vaxcyte (PCVX).
Which stock has performed better over the past year, KYMR or PCVX?
KYMR returned +74.61% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Kymera Therapeutics and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.